ArticleApplied biochemistry and biotechnology2026
Potential Role of METTL14 in Modulating Prostate Cancer Proliferation and Glycolysis Through m6A Modification of LINC01138.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study aimed to investigate the role of methyltransferase-like 14 (METTL14) in regulating proliferation and glycolysis in prostate cancer (PCa) through m6A modification of LINC01138. The expression of METTL14 and LINC01138 was analyzed in PCa tissues and cell lines (PC-3 and 22Rv1 cells). Gain- and loss-of-function experiments were performed to evaluate their effects on cell proliferation, migration, invasion, apoptosis, and glycolysis. m6A-related assays were conducted to examine the interaction between METTL14 and LINC01138. In addition, a xenograft mouse model was established to assess the in vivo role of METTL14 in PCa progression. METTL14 was significantly downregulated in prostate cancer and its low expression correlated with advanced TNM stage and distant metastasis. Functional experiments showed that METTL14 overexpression suppressed proliferation, migration, invasion, and glycolytic activity in PCa cells, whereas METTL14 knockdown produced the opposite effects. Mechanistically, METTL14 promoted the m6A modification of LINC01138, leading to its downregulation. Rescue experiments further demonstrated that LINC01138 overexpression reversed the inhibitory effects of METTL14 on tumor progression and glycolysis. In vivo, METTL14 overexpression reduced tumor growth and LINC01138 expression in xenograft models, consistent with the in vitro findings. These findings suggest a potential role of the METTL14-LINC01138 axis in prostate cancer progression and glycolysis. Further studies are warranted to elucidate the precise downstream mechanisms linking LINC01138 to glycolysis and malignant behavior.
Indexed as
Identifiers
42412271What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.